Optiscan has been featured in Stockhead, The Australian, and 11 News Corp mastheads as part of the ASX Quarterly Health Wrap, highlighting resilience among listed healthcare companies despite global market uncertainty.

• The article details several key updates from Optiscan’s Q2 FY25 report, including:
• The unveiling of InForm, Optiscan’s next-generation microscopic medical imaging device for pathology lab workflows
• Completion of the beta phase of its cloud-based Telepathology platform, with user feedback driving key enhancements ahead of MVP delivery in Q4 FY25
• Progress toward veterinary market entry, with a dedicated prototype device set to be unveiled this quarter
• Preparations for a clinical trial at Royal Melbourne Hospital, with patient recruitment expected in Q4 FY25 and data to inform planned US clinical trials in FY26
• Continued work on regulatory strategy for InVue and InForm, supported by expert consultants
• Facility upgrades to support increased manufacturing, assembly, and R&D capacity
• Receipt of a $1.775M R&D tax refund, boosted by a successful Advance and Overseas Finding application

Stockhead – Read the full article here
The Australian – Read the full article here